Literature DB >> 19369466

The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice.

J Timothy Harrington1.   

Abstract

OBJECTIVE: To evaluate the uses of quantitative disease activity scoring and a physician global assessment of disease activity for managing rheumatoid arthritis (RA) in rheumatology practice.
METHODS: The Global Arthritis Score (GAS) and a physician global assessment (Physician Global) were determined during each office visit for a community practice RA population. The GAS was calculated from patients' self-reported pain, functional assessment, and tender joint count. The Physician Global was recorded on a 10-point visual analog scale. The correlation of these 2 disease activity measures was determined for the most recent office visit of 185 patients with RA, and the reasons for discordant results were identified by chart review.
RESULTS: The GAS and Physician Global were concordant for active or inactive disease in 126 of 185 patients (68%) and were discordant in 59 (32%). Forty-five of these discordant patients had a high GAS while their Physician Global indicated inactive disease. Their GAS values were high because of osteoarthritis, back pain, soft tissue rheumatism, and/or prior joint damage rather than active RA. The other 14 patients had a low GAS with an uncontrolled Physician Global for a variety of reasons.
CONCLUSION: (1) An RA disease activity score and a quantitative Physician Global can be measured during rheumatology office visits to document patients' disease status. (2) Disease activity scoring contributes valuable information, but should not replace the Physician Global in guiding RA patient management or reimbursement decisions.

Entities:  

Mesh:

Year:  2009        PMID: 19369466     DOI: 10.3899/jrheum.081046

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis.

Authors:  Wietske Kievit; Laura van Hulst; Piet van Riel; Liana Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.

Authors:  Leslie R Harrold; J Timothy Harrington; Jeffrey R Curtis; Daniel E Furst; Mary Jane Bentley; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg
Journal:  Arthritis Rheum       Date:  2012-03

Review 3.  Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study.

Authors:  Sonali P Desai; Jinoos Yazdany
Journal:  Arthritis Rheum       Date:  2011-12

Review 4.  Management and outcomes of pregnancy with or without lupus nephritis: a systematic review and meta-analysis.

Authors:  Jiayue Wu; Jinghang Ma; Wei-Hong Zhang; Wen Di
Journal:  Ther Clin Risk Manag       Date:  2018-05-11       Impact factor: 2.423

5.  Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: a systematic review following COSMIN guidelines.

Authors:  Tim Pickles; Rhiannon Macefield; Olalekan Lee Aiyegbusi; Claire Beecher; Mike Horton; Karl Bang Christensen; Rhiannon Phillips; David Gillespie; Ernest Choy
Journal:  RMD Open       Date:  2022-03

6.  Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis.

Authors:  Jos Hendrikx; Marieke J de Jonge; Jaap Fransen; Wietske Kievit; Piet Lcm van Riel
Journal:  RMD Open       Date:  2016-08-18

7.  Focus group interviews reveal reasons for differences in the perception of disease activity in rheumatoid arthritis.

Authors:  Margot J M Walter; Adriaan Van't Spijker; Annelieke Pasma; Johanna M W Hazes; Jolanda J Luime
Journal:  Qual Life Res       Date:  2016-07-21       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.